A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic her2+ breast cancer (her2climb-05).
Principal investigator: Johanna Mattson
HUS Comprehensive Cancer Center
